Metatron ($MRNJ) Public Marijuana Company Deal D
Post# of 617763
DOVER, DE--(Marketwired - May 18, 2017) - Metatron (
Visit http://kinddistco.com to see their product line
North American marijuana sales grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expanded in the U.S. and Canada, according to a new report by Arcview Market Research. Attorney General Jeff Sessions has been in opposition to relaxing marijuana restrictions, and as announced in a recent report from Newsweek.com, Congress won't give Sessions any money to fight a war on state laws to legalize marijuana. A growing market, coupled with more legislative seeing the potential in this industry, should only lead to a higher value than what was forecasted for marijuana public and private companies. Metatron continues to remind its shareholders the aggressive strategy that's designed to ensure success in an active and liquid market for its products.
Metatron, Inc. has introduced Series B Preferred Shares Metatron approved investors can acquire Series B shares in blocks of various sizes. The first round investors will receive the highest discount. Series B shares can be redeemed through the Company, are immune to reverse splits, and will convert at 1 B share to 50,000 common shares. For more information, please visit metatronstock.com.
Metatron's Apps: iTunes: https://itunes.apple.com/us/artist/i-mobilize...d325075390 Google Play: https://play.google.com/store/apps/developer?id=Metatron+Inc Facebook: http://www.facebook.com/metatroninc Twitter: http://twitter.com/metatroninc News: http://metatroninc.com/blog
Forward-Looking Statements: Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results of the specific items described in this release, and the company's operations generally, to differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's need for additional financing, which is not assured and which may result in dilution of shareholders, the company's status as a small company with a limited operating history, dependence on third parties and the continuing popularity of the iOS operating system, general market and economic conditions, technical factors, receipt of revenues, and other factors, many of which are beyond the control of the company. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements, and we disclaim any obligation to update information contained in any forward looking statement. Metatron retained Global Discovery Group Inc. for $30,500 for consulting services, CSC Partners for $1,500, Bas1 for $2501 and the company retained Pacific Equity Alliance LLC by issuing Integrative Business Alliance LLC 100m rule 144 for 1 year consulting services. Metatron does not grow, sell or distribute any substances that violate United States Law or the Controlled Substances Act.
Contact: Metatron, Inc. Joe Riehl 302-861-0431 ir@metatroninc.com
(0)
(0)